Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention

Guangdong Provincial People's Hospital88,938 enrolled

Overview

As a single center, retrospective observation study in Guangdong Institute of Cardiovascular Diseases, this study included the main study population of patients who underwent coronary angiography and / or coronary intervention from January 2007 to Decemeber 2018. The hospitalization information was collected in the form of direct derivation of the case, and cardiac and renal adverse events were collected through outpatient recorder system. All-cause death information was obtained from the Public Security and matched to the electronic Clinical Management System of the Guangdong Provincial People's Hospital records.

This is a single center, retrospective observation study collecting data on 88938 coronary angiography and / or coronary intervention patients from January 2007 to Decemeber 2018. Data regarding demographic information, admission diagnoses and history of present illness, biomarkers and details on preventive hydration and medications will be collected. The primary endpoint of this study is All-cause mortality, and secondary endpoints are Adverse Cardiovascular and Kidney Events.

Study Type

OBSERVATIONAL

Enrollment

88,938

Conditions

Cardio-Renal Syndrome Coronary Angiography Coronary Artery Disease Kidney Diseases Metabolic Syndrome

Outcomes

Primary Outcomes

All-cause mortality

Admission Patients Died for all-cause mortality within 13 years.

Time frame: From hospital admission to 13 years follow-up

Secondary Outcomes

Contrast-Induced Acute Kidney Injury (CI-AKI 0.3)

defined as a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure

Time frame: 48 hours

Cystatin C based CI-AKI (CI-AKI cyc)

Cystatin C based CI-AKI, defined as a ≥10% absolute increase in serum cystatin C during the first 24 hours after the procedure and and a ≥ 0.3 mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure.mg/dL absolute increase in serum creatinine from baseline during the first 48 hours after the procedure

Time frame: 24-48 hours

The change of eGFR, calculate based on CrCl and serum cystatin C

The eGFR creatinine-cystatin C was calculated by the 2012 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C equation: 135 \*min(Scr/κ, 1)α \* max(Scr/κ, 1)-0.601 \* min(Scys/0.8, 1)-0.375 \* max (Scys/0.8, 1)-0.711 \* 0.995Age \[\* 0.969 if female\] \[\* 1.08 if black\], where Scr is serum creatinine, Scys is serum cystatin C, κ is 0.7 for females and 0.9 for males, α is -0.248 for females and -0.207 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.

Time frame: 48-72 hours

Contrast-induced Persistent kidney injury (CI-PKI)

Serum creatinine was measured by endpoint colorimetry or enzymatic assays. CI-PKI was defined as residual impairment of renal function indicated by a ≥ 25% reduction in creatinine clearance at 3 months in comparison with baseline. comparison with baseline

Time frame: 3 months

Incidence of major adverse cardiovascular events

all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events.

Time frame: 3-12months

Follow-up major adverse cardiovascular and clinical events

We will follow up the patients by telephone and outpatient service to know the one year all-cause mortality (cardiovascular and noncardiovascular) and cardiovascular events.